DiscGenics

DiscGenics

Biotechnology Research

Salt Lake City, Utah 3,083 followers

REVOLUTIONIZING CARE FOR CHRONIC BACK PAIN

About us

DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we hope will be a profound therapeutic option for millions of patients suffering from the debilitating effects of back pain. DiscGenics’ first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy for the treatment of patients with mild to moderate degenerative disc disease.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Salt Lake City, Utah
Type
Privately Held
Founded
2007

Locations

Employees at DiscGenics

Updates

Similar pages

Browse jobs

Funding

DiscGenics 3 total rounds

Last Round

Series C

US$ 50.0M

See more info on crunchbase